All Drug Discovery Processes articles – Page 34
-
NewsE. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
-
ArticleScientific workflow for hypothesis testing in drug discovery: Part 1 of 3
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
-
ArticleNew insights into the role of viral capsids in gene therapy safety
Viral capsid assembly and quality are key factors in gene therapy success and safety. Here, Dr Chelsea Pratt explores how cutting-edge tools are enabling scientists to tackle these challenges and improve patient outcomes.
-
NewsNew CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
-
NewsMetrion Biosciences appoints Lee Patterson as CEO
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
-
ArticleThe paradox of data in precision medicine
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
-
NewsBreakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
-
NewsUSC partners with Autobahn Labs to accelerate drug discovery
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
-
ArticleHighlights of the AAPS 2024 Summer Scientific Forum
In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.
-
ArticleThe hidden risks of over-reliance on healthy donor material
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant ...
-
ArticleWomen in STEM with Charlotte Owens
As Senior Vice President and Head of Global Medical Affairs & Outcomes Research at the global healthcare company Organon, Charlotte Owen’s extensive work is advancing women’s healthcare and overcoming health inequities.
-
NewsPromising new bioactive material to regenerate cartilage
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
-
ArticleExploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers ...
-
ArticleWomen in STEM with Juliet Williams
As part of our series highlighting women in STEM, we spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver ...
-
NewsMini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
-
NewsCancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
-
ReportBeyond the lab: screening
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
-
ArticleT-cell receptors offer window to the cell for a new class of cancer therapeutics
Dr Daniel Kavanagh, Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG, discusses how monoclonal antibodies are limited by their ability to only recognise tumour antigens expressed on the outside surface of a cell. In this article he explains how investigational genetically engineered medicinal products are leveraging T-cell receptors ...
-
ArticleUnique self-activating proteins for drug discovery
Explore cutting-edge hit-to-lead insights through exclusive interviews and studies by leading experts in the field.
-
ArticleDrug Target Review Proteomics eBook 2023
Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.